bioAffinity Technologies (@bioAffinity) header
bioAffinity Technologies (@bioAffinity) profile picture
Joined June 2020
Photo by bioAffinity Technologies (@bioAffinity)Photo by bioAffinity Technologies (@bioAffinity)Photo by bioAffinity Technologies (@bioAffinity)Photo by bioAffinity Technologies (@bioAffinity)Photo by bioAffinity Technologies (@bioAffinity)Photo by bioAffinity Technologies (@bioAffinity)Photo by bioAffinity Technologies (@bioAffinity)Photo by bioAffinity Technologies (@bioAffinity)Photo by bioAffinity Technologies (@bioAffinity)Photo by bioAffinity Technologies (@bioAffinity)
bioAffinity Technologies retweeted
bioAffinity Technologies CEO: Record CyPath Lung testing fuels growth ambitions @bioAffinity proactiveinvestors.com/compa… #CyPath #Lungcancer #Cancer #Lung #Cytometry #AI #COPD #Asthma #BIAF
1
1
3
543
bioAffinity Technologies retweeted
This #WorldLungCancerDay, @FIRS_LungsFirst, of which the American Thoracic Society is a founding member, is raising awareness of the importance of detecting lung cancer earlier and expanding equitable access to screening worldwide. Screening high risk populations can help identify lung cancer before symptoms develop, when the disease may be more responsive to treatment. Yet access to screening remains inconsistent across countries and even within health care systems, with many eligible individuals facing barriers such as limited availability, lack of awareness, financial obstacles, or geographic challenges. Expanding screening for high-risk populations has the potential to dramatically improve survival through earlier diagnosis. Learn more: site.thoracic.org/press-rele…
5
5
996
bioAffinity Technologies retweeted
From lung surgery at 3 months to climbing 1,191 steps at the Fight For Air Climb, Luke’s resilience is nothing short of inspiring. Read how this family turned fear into strength: on.lung.org/4dvfys5
1
7
476
bioAffinity Technologies retweeted
Join our upcoming "LIVE! with Corporate Connect🎉: Virtual Investment Webinar on January 17th at 3:00 PM ET. Our spotlight this week will be on the #Healthcare sector. Joining us are key players: @bioAffinity ($BIAF), Bullfrog AI Holdings ($BFRG), and RevivaPharmaceuticals ($RVPH). Leading the discussions will be Maria Zannes, CEO of $BIAF, Vin Singh, CEO of $BFRG, and Laxminarayan Bhat, CEO of $RVPH. Don't miss out! REGISTER HERE: us02web.zoom.us/webinar/regi… Learn more about our Corporate Connect service at: webull.com/corporate-connect
2
5
1
5
14,283
bioAffinity Technologies retweeted
Because #research saves lives: The American Lung Association Research Institute is investing $22 million to support 130 top scientists finding new ways to prevent, treat and cure #lungdisease. Learn more 👉 Lung.org/research-team
2
3
264
bioAffinity Technologies retweeted
Thank you all for such a wonderful #CHEST2025! We can't wait to see you at the next CHEST Annual Meeting. Let us know what you want to learn at CHEST 2026 by submitting a topic today: hubs.la/Q03PJ3VS0
6
18
4,764
As World Lung Day approaches on Sept 25., here are some quick tips for how to improve your respiratory health: 🫁 Breathe Clean Air – Avoid polluted areas and support clean air policies. 🚭 Be Smoke-Free – Quit smoking and avoid second-hand smoke. 👟 Take the Active Option – Regular exercise supports lung function. 💉 Vaccinate – Protect against flu, pneumonia, and COVID-19. 🌿 Fight Climate Change – Support actions to reduce greenhouse gases. 🍎 Eat Well – A balanced diet supports overall respiratory health. For more tips, and to learn more about our upcoming World Lung Day events, check out: site.thoracic.org/press-rele…
1
8
8
1,518
bioAffinity Technologies retweeted
⚠️ A new law guts #Medicaid and #healthcare coverage, jeopardizing care for many Americans. It also rolls back clean-air controls, putting us all in danger. Learn what’s changing and how to protect your health: on.lung.org/3KcPBkc
1
334
bioAffinity Technologies retweeted
Every person with COPD deserves access to education and support. Share this post and help us reach those who need it most. Lung.org/COPD
1
2
1
3
389
bioAffinity Technologies retweeted
Why are investors paying closer attention to @bioAffinity $BIAF? Because it checks the boxes: clinical validation, insurance reimbursement, commercial momentum, and health system impact. CyPath® Lung is more than a test: it’s a platform for building long-term diagnostic value. Learn more: bit.ly/414hpgm $BIAF $AZN $KURA $PFE $AMGN
2
6
314
Life With Cancer: Aging is the privilege that you hope for. #cancer #lungcancer #cancersucks
10
1
21
1,485
bioAffinity Technologies retweeted
Christy had a 2% chance of survival. Today, she’s a 17-year lung cancer survivor. 💙 Research saved her life and more breakthroughs are within reach. Give now and your donation will be TRIPLE MATCHED. action.lung.org/site/Donatio… #LungHealth #TripleMatch #DonateNow
1
5
532
The annual ATS Women's Forum recognizes the achievements and supports the advancement of women in pulmonary, critical care, and sleep medicine and research. This year, Yolanda Mageto, MD, MPH, ATSF, discussed her experiences during the forum. Additionally, the Elizabeth A. Rich, MD Award, recognizing outstanding contributions to the advancement of women in pulmonary medicine, was awarded to Loretta G. Que, MD. ATS thanks United Therapeutics, Sanofi | Regeneron and Genentech, Inc. for their generous support of the Women's Forum.
2
9
1,363
bioAffinity Technologies retweeted
We’re excited to announce a new #research grant, in partnership with @accpchest. This funding opportunity, focused on #COPD management, honors our 120-year legacy of advancing #lunghealth through public health and clinical initiatives. on.lung.org/3Fjx43H.
1
1
3
1,686
bioAffinity Technologies retweeted
👨‍⚕️ bioAffinity Technologies $BIAF: Strengthens Leadership with Appointment of Chief Medical Officer Dr. Gordon Downie @bioAffinity has named Dr. Gordon Downie, MD, PhD, as Chief Medical Officer—a strategic hire as the company scales its CyPath® Lung test nationwide. Dr. Downie brings 30+ years of expertise in pulmonary medicine, early cancer detection, and interventional pulmonology. 💡 Why This Matters for Investors: - Clinical Expertise at the Helm: Dr. Downie’s deep background in bronchoscopy and lung cancer diagnosis aligns with CyPath® Lung’s mission to detect cancer earlier and more accurately. - Market-Driven Perspective: Having practiced in underserved rural regions, he understands real-world diagnostic gaps and the urgent need for scalable, noninvasive solutions. - Innovation Meets Execution: His leadership is expected to accelerate clinical adoption and expand access to $BIAF's CyPath® Lung as demand for early lung cancer detection grows. 📄 redchip.com/stocks/biaf/news… $BIAF $AZN $KURA $PFE $AMGN #BiotechStocks #LungCancer #LeadershipUpdate #Diagnostics #HealthcareInnovation #Investors
1
4
297
bioAffinity Technologies retweeted
📈 bioAffinity Technologies $BIAF: CyPath® Lung Sales Surge 276% YoY in Q1 2025 @bioAffinity reports strong momentum in Q1 2025, with $1.9M in revenue and a 276% year-over-year increase in CyPath® Lung sales, driven by U.S. commercial expansion. 💡 Why This Matters to Investors: - Commercial Growth: CyPath® Lung scaling rapidly, with 600+ tests delivered in 2024 and growing Q1 adoption. - Operational Efficiency: Strategic actions expected to reduce costs by $3.8M annually and improve margins. - Tech-Driven Scalability: 50% increase in data throughput and 25%+ cost reduction per test without impacting accuracy. - Global IP Expansion: Australian patent accepted, supporting international commercialization strategy. 🔗 Read Full Results: redchip.com/stocks/biaf/news… $BIAF $AZN $KURA $PFE $AMGN #BIAF #BiotechStocks #LungCancer #EarlyDetection #HealthcareInnovation #InvestorInsights #Diagnostics #AIinHealthcare #SmallCapStocks
1
6
312
bioAffinity Technologies retweeted
🎙️ Exclusive Interview: bioAffinity Technologies $BIAF CEO Maria Zannes on Revolutionizing Lung Cancer Diagnostics Lung cancer is the leading cause of cancer deaths, yet early detection remains elusive. @bioAffinity is changing that with CyPath® Lung, a noninvasive test that’s shown 92% sensitivity and 88% accuracy in detecting early-stage lung cancer. 💡 Why Investors Should Tune In: 📈 217% Q/Q order growth in Q2 2024 signals accelerating demand. 🏥 Federal Supply Schedule approval opens access to U.S. veterans—a market treating ~8,000 lung cancer cases annually. 🌍 Positioned for expansion in the $4.7B global lung cancer diagnostics market. 🔬 Plus, hear how their AI-driven flow cytometry platform targets future growth in COPD and asthma—multi-billion-dollar markets by 2027. 📽️ Watch the full interview with CEO Maria Zannes now: 🔗 youtu.be/cvqLqOX1n8o?si=F4wF… $BIAF $AZN $KURA $PFE $AMGN #BIAF #BiotechStocks #LungCancer #EarlyDetection #HealthcareInnovation #InvestorInsights #Diagnostics #AIinHealthcare #SmallCapStocks
2
4
277
bioAffinity Technologies retweeted
🎙️ Exclusive Interview: bioAffinity Technologies $BIAF CEO Maria Zannes on Revolutionizing Lung Cancer Diagnostics Lung cancer is the leading cause of cancer deaths, yet early detection remains elusive. @bioAffinity is changing that with CyPath® Lung, a noninvasive test that’s shown 92% sensitivity and 88% accuracy in detecting early-stage lung cancer. 💡 Why Investors Should Tune In: 📈 217% Q/Q order growth in Q2 2024 signals accelerating demand. 🏥 Federal Supply Schedule approval opens access to U.S. veterans—a market treating ~8,000 lung cancer cases annually. 🌍 Positioned for expansion in the $4.7B global lung cancer diagnostics market. 🔬 Plus, hear how their AI-driven flow cytometry platform targets future growth in COPD and asthma—multi-billion-dollar markets by 2027. 📽️ Watch the full interview with CEO Maria Zannes now: 🔗 youtu.be/cvqLqOX1n8o?si=F4wF… $BIAF $AZN $KURA $PFE $AMGN #BIAF #BiotechStocks #LungCancer #EarlyDetection #HealthcareInnovation #InvestorInsights #Diagnostics #AIinHealthcare #SmallCapStocks
1
5
243
bioAffinity Technologies retweeted
🚀 bioAffinity Technologies $BIAF: Major Efficiency Gains for CyPath® Lung Test! @bioAffinity has significantly enhanced the efficiency of its CyPath® Lung diagnostic, a noninvasive test for early lung cancer detection. Key updates include: ✅ 50% Faster Data Acquisition ✅ 60% Lower Sample Processing Costs ✅ 25%+ Decrease in Per-Test Cost ✅ No Changes to Patient Experience or Test Accuracy (92% sensitivity, 87% specificity) 🧪 These improvements boost lab throughput by over 10%, reduce reagent use, and preserve test performance—strengthening CyPath® Lung’s position as a cost-effective and scalable solution in the fight against lung cancer. 💰 A recent economic study showed potential U.S. healthcare savings of up to $1.27 billion annually if CyPath® Lung were integrated into standard care. 📄 redchip.com/stocks/biaf/news… $BIAF $AZN $KURA $PFE $AMGN #BiotechStocks #LungCancer #EarlyDetection #HealthcareInnovation #Investing
1
1
5
8,489